Clinical and genetic characterization of PYROXD1-related myopathy patients from Turkey

Hülya-Sevcan Daimagüler1,2 | Ugur Akpulat1,2,3 | Özkan Özdemir1,2
Uluc Yis4 | Serdal Güngör5 | Beril Talim6 | Gülden Diniz7 | Figen Baydan8,9 | Holger Thiele10 | Janine Altmüller10 | Peter Nürnberg2,10 | Sebahattin Cirak1,2

1Department of Pediatrics, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
2Center for Molecular Medicine Cologne (CMMC), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
3Department of Medical Biology, Faculty of Medicine, Kastamonu University, Kastamonu, Turkey
4Faculty of Medicine, Department of Pediatric Neurology, Izmir, Dokuz Eylûl University, Izmir, Turkey
5Faculty of Medicine, Turgut Ozal Research Center, Department of Paediatric Neurology, Inönü University Malatya, Malatya, Turkey
6Pediatric Pathology Unit, Department of Pediatrics, Hacettepe University Ankara, Ankara, Turkey
7Department of Pathology, Ankara University, Ankara, Turkey
8Division of Child Neurology, Tepecik Training and Research Hospital, Izmir, Turkey
9Neuromuscular Disease Center, Tepecik Training and Research Hospital, Izmir, Turkey
10Cologne Center for Genomics (CCG), University of Cologne and University Hospital Cologne, Cologne, Germany

Correspondence
Dr. Sebahattin Cirak, Department of Pediatrics, Faculty of Medicine and University Hospital Cologne, University Hospital Cologne, Kerpener Straße 62, 50937 Köln, Cologne, Germany.
Email: sebahattin.cirak@uk-koeln.de

Abstract
Congenital myopathies (CMs) are a heterogeneous group of inherited muscle disorders characterized by muscle weakness at birth, while limb-girdle muscular dystrophies (LGMD) have a later onset and slower disease progression. Thus, detailed clinical phenotyping of genetically defined disease entities are required for the full understanding of genotype–phenotype correlations. A recently defined myopathic genetic disease entity is caused by bi-allelic variants in a gene coding for pyridine nucleotide-disulfide oxidoreductase domain 1 (PYROXD1) with unknown substrates. Here, we present three patients from two consanguineous Turkish families with mild LGMD, facial weakness, normal CK levels, and slow progress. Genomic analyses revealed a homozygous known pathogenic missense variant (c.464A>G, p.Asn155Ser) in family 1 with two affected females. In the affected male of family 2, we found this variant in a compound heterozygous state together with a novel frameshift variant (c.329_332delTCTG, p.Leu112Valfs*8), which is the second frameshift variant known so far in PYROXD1. We have been able to define a large homozygous region in family 1 sharing a common haplotype with family 2 in the critical region. Our data suggest that c.464A>G is a Turkish founder mutation. To gain deeper insights, we performed a systematic review of all published PYROXD1-related myopathy cases. Our analysis showed that the c.464A>G variant was found in 87% (20/23) of the patients and that it may cause either a childhood- or adult-onset phenotype, irrespective of its presence in a homozygous or compound heterozygous state. Interestingly, only four patients had elevated CK levels (up to 1000 U/L), and cardiac involvement was found in few compound heterozygous cases.

Keywords
congenital myopathy, haplotype analysis, LGMD, Mendeliome, PYROXD1, whole exome sequencing

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2021 The Authors. American Journal of Medical Genetics Part A published by Wiley Periodicals LLC.
1 | INTRODUCTION

The congenital myopathies (CMs) are a heterogeneous group of rare hereditary muscle diseases manifesting with hypotonia and muscle weakness pre- or perinatally and are characterized histopathologically by distinctive structural lesions within the skeletal muscle (Walton & Nattrass, 1954). CMs have been classified into five subgroups based on the predominant structural pathological hallmarks present on skeletal muscle biopsies: core myopathies, nemaline myopathies, centronuclear myopathies, congenital fiber-type disproportion myopathy, and myosin storage myopathy (Claeys, 2020; Scoto et al., 2013; Wang et al., 2018). This histopathological classification has been amended by the etiological classification based on the associated (mutated) gene since the underlying causal defects leading to CMs are Mendelian gene mutations (Claeys, 2020).

One of the latest identified disease-associated genes for CMs presenting with overlapping clinical and histopathological features of core, centronuclear, myofibrillar, and nemaline myopathies is the pyridine nucleotide-disulfide oxidoreductase domain 1 (PYROXD1) gene (O’Grady et al., 2016). The first publication of the phenotypes associated with pathogenic variants in PYROXD1 revealed an early-onset myopathic disease with slow progression but also with signs of dystrophy in the muscle biopsies and myofibrillar alterations, mostly in families with Turkish origin (O’Grady et al., 2016). Subsequent publications revealed PYROXD1 variants causing congenital myopathy but, interestingly, showing that patients with an adult-onset muscular dystrophy phenotype as well (Lornage et al., 2019; O’Grady et al., 2016; Saha et al., 2018; Sainio et al., 2019) are having the same variant c.464A>G, p.Asn155Ser in a homozygous or compound heterozygous state. Thus, the genotype–phenotype correlation of PYROXD1-related primary muscle disease has not been well understood because of the wide clinical spectrum of reported phenotypes.

In this report, we describe three Turkish cases presenting with an early-onset and slow progression of muscle weakness. We performed detailed clinical, genetic, and histopathological investigation. To enhance our understanding of the PYROXD1-related myopathies, we performed a systematic review of all published cases. These findings prompted us to investigate if this particular variant could be a founder mutation in families of Turkish descent. Indeed, haplotype analyses confirmed that c.464A>G is a founder mutation in the Turkish population.

2 | MATERIAL AND METHODS

2.1 | Histopathology studies

The muscle biopsy at the age of 12 years from Patient 1 (Yis et al., 2018) and at the age of 8 years from Patient 3 was processed with standard techniques and was analyzed histologically as described elsewhere (Dubowitz & Sewry, 2013). Additionally, immunohistochemistry was performed using myosin antibody (Novocastra, UK, NCL-myosin), and the neonatal myosin heavy chain antibody (Novocastra, UK, NCL-MHCn) was used for the identification of immature fibers (further details in Supplementary Data [Appendix S1]).

2.2 | Genomic analyses

For Patient 3, initially we performed Mendeliome sequencing with Illumina TruSight One (Illumina, San Diego, California, USA) on an Illumina HiSeq 2000 (Wunderlich et al., 2018), but no convincing pathogenic variant could be identified. Later, we used the Agilent SureSelect V6 enrichment kit for whole-exome sequencing (WES) on a HiSeq 4000 sequencer (Illumina, USA) for Patients 1 and 3 with a paired-end 76-bp sequencing protocol according to the manufacturer’s recommendations (Wang et al., 2018). Data analysis for both patients was performed with the in-house software Varbank of the Cologne Center for Genomics (Dafsari et al., 2019; Per-gande et al., 2020). In brief, technical details on data analysis and variant filtering are given in the Supplementary Data (Appendix S1). Variants were filtered for rare (minor allele frequency 0.1%) homozygous variants (allele read frequency of 75%–100%) in accordance with the expected autosomal recessive mode of inheritance and the known consanguineous background for both patients, as well as for compound heterozygous constellations for both patients. Variants were classified based on their potential pathogenicity (Supplementary data [Appendix S1]). Sanger sequencing was used for the validation of candidate variants in PYROXD1 and TTN (data not shown) as well as cosegregation analysis.

2.3 | Systematic literature survey and statistical analyses

We have performed descriptive statistical analysis for all PYROXD1 patients published in PUBMED (https://www.ncbi.nlm.nih.gov/pubmed/) including the three patients reported here (Lornage et al., 2019; O’Grady et al., 2016; Saha et al., 2018; Sainio et al., 2019) (further details are given on methods in Supplementary data [Appendix S1]).

2.4 | Haplotype analysis

For haplotype analysis of the mutation NM_024854.3:c.464A>G (GRCh37/hg19) on chromosome 12 at cytoband p12.1 (chr12:21452130A>G), microsatellite markers were genotyped by PCR with fluorescently labeled primers (Supplementary Table 6–8) and subsequent fragment analysis performed on an ABI 3730XL sequencer (Applied Biosystems). GeneMarker software (Gene Marker Version 1.51) was used for allele calling. Single nucleotide polymorphisms (SNPs) were genotyped by Sanger sequencing of all family members (Supplementary Figure 2–6). For both families (Figure 3), haplotypes were reconstructed manually and visualized with HaploPainter version 1 (further information is given in Supplementary data [Appendix S1]).

3 | RESULTS

3.1 | Clinical description

Patient 1 was a 17-year-old female and the sixth child of Turkish consanguineous parents (Table 1). The sibling of Patient 1, who is the
| ID  | Genetic variant | Ethnicity (paper) | Consanguinity | Current age/age of onset [y] | Muscle weakness | High CK | Cardiac involvement | Facial weakness | Swallowing difficulty | Speech difficulty | Ptosis | Respiratory involvement | Neuropathy signs (Hyporeflexia) | Others |
|-----|-----------------|-------------------|---------------|----------------------------|----------------|---------|---------------------|----------------|----------------------|-------------------|--------|------------------------|-------------------------------|--------|
| 1a  | c.285 + 1G > A   | European (Grady et al.) | N             | 29/5                       | Symmetrical, axial | N       | Y                   | Y              | N                    | Y                 | N      | Reduced or absent       | N                             |        |
| 1b  | c.285 + 1G > A   | European (Grady et al.) | N             | 26/8                       | Symmetrical, axial | Y (up to 1000 U/L) | N       | Y                   | N              | Y                   | N                  | N      | Reduced or absent       | N                             |        |
| 2a  | c.464A > G, p. (Asn1555ser) | Persian - Jewish (Grady et al.) | N             | 7/infantile                | Symmetrical, axial | N       | Y                   | Y              | Y                    | Y                 | N      | Reduced or absent       | N                             |        |
| 2b  | c.464A > G, p. (Asn1555ser) | Persian - Jewish (Grady et al.) | N             | 9/6                        | Symmetrical, axial | N       | N                   | Y              | Y                    | Y                 | N      | Reduced or absent       | N                             |        |
| 3   | c.464A > G, p. (Asn1555ser) | Turkish (Grady et al.) | Y             | 15/4                       | Symmetrical       | N       | Y                   | Y              | N                    | N                 | N      | Reduced or absent       | N                             |        |
| 4   | c.464A > G, p. (Asn1555ser) | Finnish (Sainio et al.) | N             | 65/49                      | Proximal, distal abnormal | N       | N                   | N              | N                    | N                 | N      | Reduced or absent       | N                             |        |
| 5a  | Hom., c.464A > G, p. (Asn1555ser) | Turkish (Grady et al.) | Y             | 31/10                      | Symmetrical, axial | Y (up to 700 U/L) | N       | Y                   | N              | Y                   | N                  | N      | Reduced or absent       | N                             |        |
| 5b  | Hom., c.464A > G, p. (Asn1555ser) | Turkish (Grady et al.) | Y             | 21/10                      | Symmetrical, axial | Y (up to 800 U/L) | N       | Y                   | N              | Y                   | Mild               | Y      | Reduced or absent       | N                             |        |
| 6a  | Hom., c.464A > G, p. (Asn1555ser) | Turkish (Grady et al.) | Y             | 22/2                       | Symmetrical, axial | Y (up to 700 U/L) | N       | Y                   | N              | Y                   | Mild               | N      | Reduced or absent       | N                             |        |
| 6b  | Hom., c.464A > G, p. (Asn1555ser) | Turkish (Grady et al.) | Y             | 17/2.5                     | Symmetrical, axial | Y (up to 376 U/L) | N       | Y                   | N              | Y                   | Mild               | N      | Reduced or absent       | N                             |        |
| 7   | Hom., c.464A > G, p. (Asn1555ser) | Sudanese (Saha et al.) | Y             | 37/9                       | Proximal symmetrical | N       | N                   | N              | N                    | N                 | N      | Reduced or absent       | N                             |        |
| 8   | Hom., c.464A > G, p. (Asn1555ser) | Finnish (Sainio et al.) | N             | 65/10                      | Myopathic changes, atrophic upper back muscles | Y (up to 340 U/L) | N       | Y                   | NA             | N                    | Mild               | Episodic dyspnea, FVC 40% (64y) | Normal | Ambulant with two sticks. |
| 9a  | Hom., c.464A > G, p. (Asn1555ser) | Finnish (Sainio et al.) | N             | 70/30                      | Myopathic changes in proximal and paraspinus muscles, neck flexor | N       | Y, Two strokes (61y and 66y) | N              | N                    | hoarseness in his voice | N      | PVC 67% with severe reduced MIP, MEP and PCF (70y) | Normal | Ambulant with two sticks for 200 m. |
| 9b  | Hom., c.464A > G, p. (Asn1555ser) | Finnish (Sainio et al.) | N             | 70/33                      | Myopathic changes in proximal, neck flexor | N       | N                   | N              | N                    | N                 | N      | PVC 30%, death due to respiratory insufficiency (68y) | Normal | Wheelchair bound at 66y and deceased at 70y. |
| ID  | Genetic variant                                      | Ethnicity | Consanguinity | Current age/age of onset [y] | Muscle weakness | High CK | Cardiac involvement | Facial weakness | Swallowing difficulty | Speech difficulty | Ptosis | Respiratory involvement | Neuropathy signs (Hyporeflexia) | Others                                                                 |
|-----|------------------------------------------------------|-----------|---------------|-----------------------------|----------------|---------|---------------------|----------------|----------------------|------------------|--------|--------------------------|---------------------------------|------------------------------------------------------------------------|
| 10  | c.285 + 1G > A, c.464A > G, p. (Asn155Ser)          | France    | N             | NA/ neonatal                | Axial, wheelchair bound since age of 12y | NA      | NA                  | N             | NA                   | Y                | NA     | NIV and oxygen therapy since 14 | Low ears, high-arched feet | Delayed motor milestones and wheelchair bound since the age of 12 years. |
| 11  | Hom., c.464A > G, p. (Asn155Ser)                     | France    | Y             | 66/ childhood               | Axial, lower and upper limbs | NA      | NA                  | NA            | NA                   | NA               | NA     | Reduced VC with 68%       | NA                              | Walking and running difficulties.                                      |
| 12  | c.415-976A > G, c.1116G > C, p. (Gln372His)         | France    | N             | Teenager/ neonatal          | Proximal, distal, upper and lower limbs, wheelchair-bound since age 13 | NA      | NA                  | NA            | NA                   | NA               | NA     | Respiratory insufficiency requires NIV, and oxygen therapy since 14y of age | Y                               | Delayed motor milestones and wheelchair bound since 12 years of age. Younger brother same genotype died at 16 years of age. |
| 13a | Hom., c.464A > G, p. (Asn155Ser)                     | Turkish   | Y             | 17/6                        | Symmetrical more proximal but also shows distal | N(75 U/L) | N       | Y                | Y             | Y                   | Mild            | Sleep hypoventilation | N                              | N                                                                            |
| 13b | Hom., c.464A > G, p. (Asn155Ser)                     | Turkish   | Y             | 38/NA                       | NA                  | NA      | NA                  | N             | NA                   | NA               | NA     | NA                       | NA                              | N                                                                            |
| 14  | c.464A > G, p. (Asn155Ser), c.329, 332delTCTG, p.(L112Val) | Turkish   | Y             | 8/3                         | Lower and upper proximal | N(49 U/L) | N       | Y                | Y             | Y                   | NA              | N                  | Polyneuropathy | N                                                                            |
| 15  | Hom., c.464A > G, p. (Asn155Ser)                     | Persian-Jewish (Woods et al., 2020) | Y             | 46/30-33                    | Proximal | N       | N                | N             | Y                    | N                | N      | Normal                    | Sparing of the rectus femoris on magnetic resonance imaging            | (Continues)                                                                 |
oldest child, was a 38-year-old female (Patient 2), still alive and walking with support, presenting same phenotype as her sister according to the reporting parents. The fifth child and brother of Patients 1 and 2 (Figure 2(a)-1: 1:II-5) had died at the age of 14 years (y) due to cardiomyopathy. No material of the brother was available for any genomic analyses. Patient 1, the youngest of six children, had normal perinatal history, and motor milestones were normal. Clinical examination at the age of 12 years showed a generalized reduction in the muscle bulk, symmetrical more proximal, but also showed distal muscle weakness with Gowers’ sign (Supplementary: Video 1), neck weakness and scapular winging. The creatine kinase (CK) value was normal: 75 IU/L (0–171). The deep tendon reflexes (biceps, triceps, patella, and Achilles) were absent. She started walking at 12 months of age; the first signs of muscle weakness were observed at the age of 6 years. There was mild joint laxity in the upper extremities, and no contractures were observed. She was still ambulant now at the age of 18 years. Furthermore, the patient had facial weakness, nasal speech, and mild difficulties in swallowing, without ophthalmoplegia. Nerve conduction velocities and amplitudes were normal in the left median, ulnar, and peroneal motor nerves. Sensory nerve conduction velocities and amplitudes of left median, ulnar, and sural nerve were also normal. Electromyography of left tibialis anterior, left quadriceps femoris, and right biceps muscles revealed myopathic motor unit potentials. No signs of cardiac dysfunction have been observed until now. Her cognitive and speech development was normal according to her age.

Patient 3 was an 8-year-old boy who was the first and only offspring of consanguineous (first-degree cousins) Turkish parents (Figure 1(a)-(c)). He was diagnosed at the age of 8 years with congenital myopathy with normal CK level (41 IU/L). The patient had difficulties in walking due to his falls, and he could only climb the stairs with help. Clinical examination at the age of 7 years showed a myopathic expression in a long and narrow face, large ears (Figure 1(a)), a thin hand, and long flexible fingers (Figure 1(b),(c)). The total muscle mass was decreased, but the cranial nerve examination was normal at that time. In addition, he had facial weakness, nasal speech, and difficulties with swallowing. The patient had neck muscle weakness and lower and upper proximal weakness. Myotonic reactions could not be elicited, and the cranial magnetic resonance imaging was normal. The diagnostic molecular genetic testing for fragile X syndrome was negative. At the age of 8 years, the nerve conduction velocity showed axonal neuropathy changes that were interpreted as polyneuropathy. He did not show any clinical signs of cardiomyopathy.

3.2 | Muscle biopsy findings

A muscle biopsy (Table 2) was carried out for both patients (Figure 1(d)-(h), Supplementary Figure 1(a)-(d)). An incisional biopsy from the deltoid muscle of patient 1 (Figure 1(d)-(h)) showed degenerative myopathic changes in H&E staining including fiber size variability, multiple internalized nuclei, atrophic fibers, and increased fibrous connective tissue (Figure 1(d)). NADH-TR staining showed cores in the muscle fibers (Figure 1(e)). Nemaline rods were not detected by
modified trichrome (Figure 1(f)). Neonatal myosin staining showed immature and regenerating fibers (Figure 1(g)). There were a few central inclusions expressing myotilin (Figure 1(h)). Type 2 myofibers were slightly decreased in the fast and slow myosin heavy chain staining. All the other immunohistochemical analysis showed no abnormalities (Supplementary Data [Appendix S1]). Muscle biopsy results indicated a noninflammatory myopathy.

Patient 3 had a muscle biopsy (Supplementary Figure 1(a)–(d)) performed at the age of 7 years, which showed dystrophic changes. H&E staining (Supplementary Figure 1(a),(b)) represented the presence of abundant small rounded muscle fibers with centrally located nuclei and a noticeable increment of fat tissue in the sections. The patients’ muscle biopsy clearly showed dystrophic changes with increased connective tissues within endo- and perimysium and irregular desmin aggregates in sarcoplasm (Supplementary Figure 1(c),(d)).

3.3 Genomic and haplotype results

For Patient 1 (Figure 2(a)), WES analysis revealed a homozygous variant in PYROXD1 (NM_024854.3), c.464A>G causing p.Asn155Ser (Figure 2(c),(d)). The variant had already been published as pathogenic (O’Grady et al., 2016) and reported in the Exome Variant Server (seven heterozygous cases), gnomAD (AF:0.00004624), the general
minor allele frequency without any homozygous cases, and in ClinVar (Supplementary Table 2–3). This variant was classified as pathogenic by the ACMG standards and criteria guidelines (Richards et al., 2015), and it is conserved through evolution (Figure 2(d)). In addition, our filtering results revealed different TTN variants in Patient 1 (Supplementary Table 3), which were excluded by lack of cosegregation (data not shown).

Mendeliome sequencing based on the gene list of 2013 (Wunderlich et al., 2018) did not reveal any pathogenic variants because PYROXD1 was not included in the panel. WES for Patient 3 (Figure 2(b)) revealed compound heterozygous mutations in PYROXD1 (Figure 2(c),(d)); in addition to mutation c.464A>G, p.Asn155Ser, a novel frameshift variant c.329_332del, p.Leu112Valfs*8 was found (Supplementary Table 3), which was not reported in the Exome Variant Server, gnomAD, Great Middle Eastern database (GME), Iranome, ClinVar and 1000 genomes databases (Supplementary Tables 4 and 5). We classified this variant as likely pathogenic (Richards et al., 2015).

Haplotype analysis around the c.464A>G, p.Asn155Ser (chr12: 21605064A>G) variant (Supplementary Table 9–10) was performed for both families of Turkish origin. We proved that both families share a haplotype of 282,729 bp (Figure 3 Family 1–2, red boxes). In Family

**FIGURE 2** Genomic analysis and protein domain scheme. (a),(b) Pedigrees and cosegregation of family 1 (a) with patient 1 (II:6) and patient 2 (II:1) and family 2 (b) with patient 3 (II:1). Patient 1 (II:6) clearly shows a homozygous variant (red arrow) in PYROXD1, and her older sister is affected and has the same variant. Both parents are heterozygous for this variant. Patient 3 has two variants in PYROXD1, c.464A>G, p.Asn155Ser and c.329_332del, p.Leu112Valfs*8. The father (c.464A>G, p.Asn155Ser) and the mother (c.329_332del, p.Leu112Valfs*8) of patient 3 are heterozygous for one of the two variants in PYROXD1. (c) Protein structure of PYROXD1, which has two important domains, the nuclear-cytoplasmic pyridine nucleotide-disulfide reductase (PNDR) domain (shown in purple) and the NADH-dependent nitrite reductase (NADH) domain (shown in rose). The most common variant in PYROXD1 is p.Asn155Ser (blue); other found missense mutations are p.Tyr354Cys (purple) and p.Gln372His (green). The here reported novel frameshift mutation is shown in red. Three of the variants are located in the PNDR domain of PYROXD1. (d) The variant p.Asn155Ser is conserved through evolution in different species: 1. Homo sapiens (NP_079130.2), 2. P. troglodytes (XP_520786), 3. Macaca mulatta (XP_001098386.1), 4. Bos taurus (NP_001098804), 5. Mus musculus (NP_898988), 6. R. ratti (NP_001004234), 7. Gallus gallus (XP_001264205), 8. Danio rerio (NP_957057.1), and 8. Xenopus tropicalis (NP_001120558.1). For our alignment, we used NCBI FASTA files of the different species and add this to Jalview alignment with MuscleWS using service hosted at http://www.compbio.dundee.ac.uk/jabaws (MuscleWS version 3.8.31). Afterward, secondary structure analysis on alignment was done by using JPred secondary structure analysis in Jalview, seen in here as JNetHMM. The helices are marked as red tubes and the β-sheets as green arrows in the alignment. At the end, we used a color scheme, here Blossum62, which uses white for gaps, dark purple for residues matches the consensus sequence residue, and light purple for not matching to consensus residue, but the second residue does. The consensus is also displayed in yellow from the lowest (0) to the highest one (10). [Color figure can be viewed at wileyonlinelibrary.com]
1, we found the same haplotype heterozygous in both parents and homozygous in the two affected siblings (Patients 1 and 2 in Figure 3, Family 1). No DNA material of the other three healthy siblings was available (healthy siblings are not shown in Figure 3 and Supplementary Figure 2). In the second family, Patient 3 has a second mutation in *PYROXD1* that causes a frameshift by a deletion (Figure 3, Family 2). Clearly, we have been able to show the heterozygous haplotype together with the missense variant in this family too (Figure 3, red boxes), except the mother. These findings proved the variant c.464A>G as a Turkish origin founder mutation. Comparing the genomic data including SNVs of our two patients with the published haplotype region in three Turkish families in the publication of O’Grady (O’Grady et al., 2016) revealed the same homozygous region in all Turkish families. Furthermore, we discovered a larger homozygous region in our patients by adding our microsatellites and SNP positions to the already found homozygous region in the five families. Conclusively, our analysis not only showed that c.464A>G is a founder mutation in the Turkish population, but a shared homozygous region with earlier published cases was also discovered here, indicating an identity-by-descent of this mutation in the analyzed cases (Supplementary Table 10).

**FIGURE 3** Haplotypes of family 1 and family 2. Representation of the haplotypes (GRCh37/hg19) determined for individuals with the NM_024854:3:c.464A>G (12:21452130), variant at chromosome region 12p12.1. In Figure 3, both families’ haplotypes, family 1 and family 2, were presented. For Family 1, we only showed the two female siblings (II:1 and II:2) and the deceased brother, and not included the healthy siblings, because DNA was not available for genotyping. Haplotypes were reconstructed manually from the genotypes of following markers: IAPP (12:21373538 A > G) (SNV); D12S1654 (STR); SCM3 (12:21538220–21,583,464) (STR); rs7957200 (SNV); rs2058464 (SNV); rs11046076 (SNV); rs10161132 (SNV); rs2417991 (SNV); SCM4 (12:21661778–21,661,981) (STR); and ABC9, (12:21852069 T > G) (SNV), and were visualized by the HaploPainter software. The first column shows the name of the markers, and the second column shows the allelic position on chromosome 12. Each number on haplotypes represents different alleles for a microsatellite marker, and the letters represent different alleles for each SNP. The NM_024854:3:c.329_332delTCTG (12: 21602540_21602543delTCTG) is the second compound heterozygous mutation in Family 2; the “+” indicates the deletion and the “-” indicates the wt allele without deletion. The shared founder haplotype for *PYROXD1* c.464A>G between the individuals is marked with a red box. The analysis of the two families revealed 231,492 bp homozygous region in patients from the marker D12S1654 (12:21569340) to the ABC9 SNV [Color figure can be viewed at wileyonlinelibrary.com]

### 3.4 Statistical results of systematic literature survey

The statistical analysis of the 23 included individuals shown in Table 3 (Lornage et al., 2019; O’Grady et al., 2016; Saha et al., 2018; Sainio et al., 2019) revealed that the current median age of the patients by the phenotypes is 15y, with age range from 7 to 22y for the early-onset patients, and 65 year for the adult ones, with an age range from 26 to 82 year. It represents the current age by different age groups, leading to a childhood–teenage group with an average age of 12.5 year (n = 7), adult age group with 31 year (n = 8), and an old age group with 72 year (n = 5) as current age. The age of onset of the patients, including all patients with and without the founder mutation can be divided in three groups, starting with the early-onset patients with an age range from neonatal up to 3 year resulting in an average age onset of 1.5 year (n = 11). The second group, the childhood-onset patients, has an age range from 4 to 10 year, resulting in an average age of 7.4 year (n = 10), and the adult-onset patients demonstrate an average age of onset of 32 year (n = 6). It was found that the youngest age of onset occurred during the neonatal period and the oldest one at 50 year of age, and both the cases are carrying founder mutation.
**TABLE 2** Muscle biopsy results

| ID  | Age at biopsy | Internalized nuclei | Central cores | Myofibrillar inclusions | Sarcomeric disorganization | Thin filament accumulations | Nematone rods | Fiber size variability | Fatty replacement | Increased fibrosis | Biopsy                |
|-----|---------------|---------------------|---------------|-----------------------|---------------------------|-----------------------------|---------------|-----------------------|------------------|------------------|----------------------|
| 13a | 12y           | Y                   | NA            | Y                     | NA                        | NA                          | Y             | Y                     | Y                | Y                | Myopathic changes |
| 14  | 8y            | Y                   | Y             | NA                    | Y                         | NA                          | Y             | Y                     | Y                | Y                | Myopathic changes |
| 1a  | 11y           | Y                   | Y             | Y                     | Y                         | NA                          | Y             | Y                     | Y                | Y                | Myopathic changes |
| 2a  | 4y            | Y                   | Y             | Y                     | Y                         | NA                          | Y             | Y                     | Y                | Y                | Myopathic changes |
| 3   | 10y           | Y                   | Y             | n.p.                  | N                         | N                           | Y             | Y                     | Y                | Y                | Myopathic changes |
| 5a  | 16y           | Y                   | Y             | Y                     | Y                         | NA                          | Y             | Y                     | Y                | Y                | Myopathic changes |
| 6a  | 13y           | Y (>50% of fibers)  | Y on NADH and SDH stains | N | N | N | N | NA | Y | Y | Myopathic changes |
| 4   | NA            | NA                  | NA            | NA                    | NA                        | NA                          | Y             | Y                     | NA               | Dystrophic       |
| 8   | NA            | NA                  | NA            | NA                    | NA                        | NA                          | Y             | Y                     | Y                | Dystrophic       |
| 9a  | 70y           | NA                  | NA            | NA                    | NA                        | NA                          | Y             | Y                     | NA               | Dystrophic       |
| 10  | 6y            | Y                   | Y             | Y                     | Y                         | N                           | Y             | Y                     | Y                | N                | Myopathic changes |
| 11  | 26y and 66y   | Y                   | Y             | Y                     | Y                         | N                           | Y             | Y                     | N                | Y                | Myopathic changes |
| 12  | 6y            | Y                   | Y             | Y                     | Y                         | N                           | N             | Y                     | N                | Y                | Myopathic changes |
| 15  | 37y           | Y                   | Y             | Y                     | Y                         | Y                           | Y             | Y                     | NA               | N                | Myopathic changes |

Note: The muscle biopsy results of published and here reported patients, in total 70% (14/20) of all patients, had a muscle biopsy. Patient ID matches the numbers in Table 1. In general, the biopsy was performed at a teenage age (age at biopsy), except Finnish patients because of their late onset. Most important aspects of the muscle biopsy results were listed and compared. Importantly, the fiber size variation, internal nuclei, fatty replacement, and fibrosis were listed. Furthermore, if central cores were observed, any sarcomeric disorganization, myofibrillar inclusions, or thin filament accumulations occurred. This information summarized showed dystrophic (patient 4, 8, 9a) or myopathic changes.

Abbreviations: N, no; NA, not available; Y, yes.
The age of onset of the three patients without the founder mutation was neonatal or in childhood. The percentage of the patients who are homozygous for the founder mutation are 61% \((n = 14)\), and 39% are compound heterozygous \((n = 9)\) of them having the founder mutation. The founder mutation is the only one found in homozygous state in all reported patients with \(\text{PYROXD1}\).

The most common clinical features of \(\text{PYROXD1}\)-mutated patients are facial weakness (52%), speech difficulties (56.5%), swallowing difficulties (17.4%), ptosis (21.4%), and high CK levels (26%). Cardiac involvement was only found in 17.4% of the patients, but half of the patients have a respiratory insufficiency (43.8%). Signs of neuropathy were reported in 47.8% of all reported \(\text{PYROXD1}\) patients.

In total, 14 patients out of 23 had a described muscle biopsy (60.8%) (Table 2). In Table 3, the statistical analysis revealed that the patients can be divided into three groups by their age at biopsy, starting with group (I) until the teenage age with a mean age at
9.5 year for 9/14 patients (65%), second group (II) only one patient at the age of 37 year and the last, and third group (III) with a mean age of 68 year including two of 14 patients. Most common features in the muscle biopsy were fiber size variation (85.7%), internalized nuclei (78.6%), central cores (71.4%), myofibrillar inclusions (64.3%), fatty replacement (71.4%), and fibrosis (71.4%). The muscle biopsy changes had been interpreted as myopathic for most of the patients, except the Finnish patients, who were described as dystrophic.

4 | DISCUSSION

The genomic analysis of the three patients reported here led us to PYROXD1 (Figure 2a–d). We proved that the PYROXD1 c.464A>G, p.Asn155Ser variant is a founder mutation in the Turkish population, although it was not reported in the GME Variome. The gnomAD database showed six heterozygous individuals in the healthy Finnish and another six heterozygous in the European population harboring the founder mutation. Unfortunately, no Turkish genome database exists. Our own analyses revealed that the three cases reported here were obtained from the 807 exome-sequenced patients, of which 287 were Turkish-origin patients, revealing an allele frequency of 0.0052 (3/574) for the Turkish population calculated from our in-house database. In gnomAD 10.824, Finnish patients have been sequenced, and only six heterozygous individuals were found to harbor the founder mutation, which gives an AF of 0.00055 for the Finnish population. Our haplotype analysis showed a shared haplotype of 231,492 bp spanning the variant c.464A>G, (chr12:21605064A>G) in both families (Figure 3, Family 1 and 2, red boxes). A homozygous haplotype around this variant c.464A>G (chr12:21605064A>G) was also reported by O’Grady et al. in three Turkish families (O’Grady et al., 2016). We compared the genomic data of all five Turkish families (Supplementary Table 10), which revealed the same shared homozygous region of haplotypes (348,622 bp), supporting our findings. A deeper understanding of the spatial patterns of relatedness in subpopulations could be gained by using haplotype analysis on reported PYROXD1 patients with the c.464A>G mutation.

The founder mutation has a predicted destabilizing effect on PYROXD1 by the amino acid substitution (Supplementary Figure 7A–C). The used “Dynamut” molecular dynamics prediction (described in Supplementary Data [Appendix S1]) showed that the asparaginate at position 155 (Supplementary Figure 7b), (c)–in green) is located in the α-helix (H6) of PYROXD1. Asparaginate maintains the α-helical structure by several bonds (gray-dashed line) and a main binding to tryptophan (Supplementary Figure 7b), (c)–green-dashed line) and the red-dashed H-bonds with the peptide backbone. The prediction analysis showed that replacing asparagine by serine which has an OH-group instead of a carboxamide group has a destabilizing effect on the PYROXD1 structure (Supplementary Figure 7d), (e) in green).

All published patients are listed in Table 1 and can be divided into (1) individuals with an early-onset phenotype, including facial weakness, nasal speech, and swallowing difficulties, but still ambulant with help and (2) individuals with an adult phenotype alive up to 80 years of age, showing first symptoms in the 40s or even 50s with no cardiac involvement, normal CK levels, and no facial weakness (O’Grady et al., 2016; Saha et al., 2018). The founder mutation c.464A>G has been reported to cause two different phenotypes, (i) and (ii), and it was observed either in homozygous (14/23, 61%) or compound heterozygous (6/23, 26%) state.

The Turkish founder mutation was reported in total in 14/23 (61%) patients in homozygous state; six of them have been Turkish-origin patients. All of the Turkish-origin patients were consanguineous, showed high CK levels, facial weakness (6/6), and speech difficulties (6/6). The Turkish patients also had mild ptosis (4/6), one with respiratory insufficiency (1/6) and nearly all having neuropathy signs (5/6). The non-Turkish patients showed less frequent facial weakness (1/8), speech difficulties (2/8), and ptosis (1/8), but respiratory insufficiency was found in 50% of this subgroup of patients (4/8). The age of onset in the homozygous group of all populations suggests the division in two groups, one early to childhood, from 2 to 10 years of age, including the Turkish origin patients, and the second group with an older age of onset from 30 to 50 years of age, including mostly Finnish and Persian–Jewish patients.

Only four patients in the cohort were reported with cardiomyopathy and, oddly, three of them having siblings (Table 1, patients: 1b, 2b, and 9b) without cardiac involvement. Each sibling pair has the same genotype. The most likely reason for these discordant cardiac phenotypes could be secondary genetic variants in other genes (genetic modifiers). Cases reported without the founder mutation are all compound heterozygous (3/23) (Table 1). Two of them are European siblings with an essential splice-site mutation (O’Grady et al., 2016), and one of them has a functional deep intronic mutation and is wheelchair bound since the age of 12 year (Lornage et al., 2019). Conclusively, the founder mutation has been the only reported homozygous mutation in PYROXD1 patients (Table 1, Table 3).

The function of PYROXD1 is still unknown, but it has been localized to the nucleus and sarcomeres of human muscles and zebra fish (pyroxd1) myofibers (O’Grady et al., 2016). PYROXD1 is a class I pyridine nucleotide-disulfide oxidoreductase (PNDR), predicted to have a flavin adenine dinucleotide (FAD) binding site (O’Grady et al., 2016). Three different isoforms of PYROXD1 have been described (Supplementary Figure 8 for isoform 1 and 2); besides the longest isoform (isoform 1, NM_024854.5, ENST00000240651.14, Figure 2C), two other isoforms with a shorter N-terminus are existing. Isoform 2 (NM_001350912.1, ENST00000538528.5) has same domains as isoform 1 and isoform 3 (NM_001350913.2, data not shown) containing only one domain, the PNDR domain. Isoform 1 is widely expressed among all tissues in comparison with isoform 2, which shows no expression in skeletal muscle (Supplementary Figure 8, red box and arrow). Complementation assays with PYROXD1 in yeast lacking glutathione reductase have shown its reductase activity and have also shown that the glutathione reductase activity was impaired by the missense mutation c.464A>G, p.Asn155Ser and could be rescued by human wt PYROXD1 (O’Grady et al., 2016). Glutathione reductase has an important role for the survival of cells against oxidative stress induced by, for example, reactive oxygen species (ROS) (Wu & Batist, 2013).
Recently, PYROXD2 was reported as a protein localized in the inner membrane of the mitochondria (T. Wang et al., 2019). The knockout of PYROXD2 led to increased levels of mitochondrial ROS (mtROS) (T. Wang et al., 2019), which is known to cause cellular damage and also to misfolding of mitochondrial proteins (Chandel, Schumacker, & Arch, 2001), indicating that PYROXD2 is a regulator of the mitochondrial activity and regulates mtROS levels. No functional association between PYROXD1 and PYROXD2 was reported yet, but the function of PYROXD2 as a regulator of mtROS (Wang et al., 2019) and the fact that PYROXD1 rescued the yeast glutathione reductase knockout in a complementation assay (O’Grady et al., 2016) suggested that PYROXD1 could be involved in the compensation of oxidative stress in other cellular compartments than mitochondria. Furthermore, high levels of HSP70 and glutathione reductase in patients muscle tissue in Western blot analysis suggested that PYROXD1 could be also a regulator of autophagy (Lornage et al., 2019) and ROS. PYROXD1 could be a specific regulator of the ROS in the nucleus by its localization. Interestingly, used online tools predicted a nucleus localization signal sequence for PYROXD1 from amino acid position 250–282, which predicts a transport to the nucleus by importin-alpha (Supplementary Figure 9), but PYROXD1 is also in the cytoplasm. Cores were found in the muscle biopsy of PYROXD1 patients (Figure 1(e)), which was also reported in loss-of-function mutations in SEPN1 patients muscle fibers (Marino et al., 2015; Scoto et al., 2013), additionally with small focal areas in the mitochondria (Arbogast & Ferreiro, 2010). SEPN1, also called SELENON (Varone et al., 2019), belongs to the selenoproteome which predicts a transport to the nucleus by importin-alpha (Supplementary Figure 9), but PYROXD1 is also in the cytoplasm. Cores were found in the muscle biopsy of PYROXD1 patients (Figure 1(e)), which was also reported in loss-of-function mutations in SEPN1 patients muscle fibers (Marino et al., 2015; Scoto et al., 2013), additionally with small focal areas in the mitochondria (Arbogast & Ferreiro, 2010). SEPN1, also called SELENON (Varone et al., 2019), belongs to the selenoproteome (Lescure, Gautheret, Carbon, & Krol, 1999). Mutations found in the SELENON cause congenital core myopathy phenotypes (Marino et al., 2015; Moghadaszadeh et al., 2001) and are leading to alteration of the antioxidant systems (Arbogast et al., 2009) and Ca²⁺ homeostasis (Marino et al., 2015) in muscles. Low levels of ROS and NO are produced in a healthy muscle, important for the excitation–contraction coupling and signal transduction. Higher levels of both, ROS and NO after exercise could lead to oxidative and nitrosative stress in the muscle, if not regulatory mechanism fail, leading to dysfunction or lethality of the myofibers. Arbogast et al., was the first to analyze intracellular oxidant activity in human SELENON-mutated fibroblast and myotubes and showed that they contained high levels of oxidized sarcomeric protein in OxyBlot’s. These findings indicate a specific disease mechanism of ROS-related myopathies and SELENON deficiencies (Arbogast et al., 2009). As we know that PYROXD1 is a regulator of ROS in the muscle, like SELENON (Arbogast et al., 2009), we hypothesize that hyperoxidation of contractile muscle proteins could be a specific disease mechanism for PYROXD1-related myopathies. This could be confirmed by utilizing OxyBlot kit from patients’ muscle biopsies. Further research in patient material and in murine models would be required to understand the biological role of PYROXD1 against oxidative stress in skeletal muscle.

5 | CONCLUSION

In this study, we report three patients with an early-onset myopathy due to PYROXD1 mutations. Our in-depth haplotype analyses proved that the c.464A>G, p.Asn155Ser substitution is a founder mutation in the Turkish population. Our systematic literature review revealed that the PYROXD1 missense variant c.464A>G, p.Asn155Ser is the only homozygous PYROXD1 mutation reported so far and may cause an early- or an adult-onset phenotype, irrespective of if its occurrence either in the homozygous or compound heterozygous state. Cardiac involvement was rare. CK levels in PYROXD1-related myopathies were usually below 1000 U/L.

ACKNOWLEDGMENTS

We thank the patients and their families contributing to this clinical study. This work was supported by the Deutsche Forschungsgemeinschaft, Germany grants (CI 218/1-1) and Köln Fortune Grants to SC. Open access funding enabled and organized by Projekt DEAL.

CONFLICT OF INTEREST

The authors report no conflict of interest for this manuscript with the title “Clinical and genetic characterization of PYROXD1-related myopathy patients from Turkey.”

AUTHOR CONTRIBUTIONS

Manuscript writing, genetic data and bioinformatics analysis, and sequencing were performed by Hülya-Sevcan Daimagüler. UA contributed to manuscript writing. OO contributed to haplotype analysis, figure generation and manuscript writing. Patient clinical and histopathological observations were collected by Uluc Yis, Serdal Güngör, Beril Talim, Gülden Diniz, and Figen Baydan. Holger Thiele, Janine Altmüller, and Peter Nürnberg provided NGS data. Analysis of WES data, funding, study design, manuscript writing, and supervision of the study was provided by Sebahattin Cirak. All Authors have critically reviewed and approved the manuscript.

ETHICS STATEMENT

Informed consent was obtained by the families. The genetic study was approved by the local institutional review board of the University Hospital Cologne, and informed consent for genetic workup was obtained from the patients and family members.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Hülya-Sevcan Daimagüler https://orcid.org/0000-0001-8874-8125
Özkan Özdemir https://orcid.org/0000-0002-2647-6416

REFERENCES

Arbogast, S., Beuvin, M., Fraysse, B., Zhou, H., Muntoni, F., & Ferreiro, A. (2009). Oxidative stress in SEPN1-related myopathy: From pathophysiology to treatment. Annals of Neurology, 65(6), 677–686. https://doi.org/10.1002/ana.21644
Arbogast, S., & Ferreiro, A. (2010). Selenoproteins and protection against oxidative stress: Selenoprotein N as a novel player at the crossroads.
